Objective: To compare and analyze the differences in vaginal microecological characteristics between populations with ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...
More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...
Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics ...
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...
ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...
University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
A biotech start-up says the ovaries may hold clues to aging — a finding that could reshape IVF while opening a frontier in women’s health.
JSKN003 targets HER2 epitopes, releasing topoisomerase I inhibitors, providing selective antitumor activity with reduced hematological toxicity in PROC. Fast track designation allows Alphamab Oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback